BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 26028353)

  • 1. Update on the role of Interleukin 17 in rheumatologic autoimmune diseases.
    Konya C; Paz Z; Apostolidis SA; Tsokos GC
    Cytokine; 2015 Oct; 75(2):207-15. PubMed ID: 26028353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of IL-17 in the Human Immune System and Its Blockage as a Treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis.
    Jaller Char JJ; Jaller JA; Waibel JS; Bhanusali DG; Bhanusali N
    J Drugs Dermatol; 2018 May; 17(5):539-542. PubMed ID: 29742185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti cytokine therapy in chronic inflammatory arthritis.
    Thompson C; Davies R; Choy E
    Cytokine; 2016 Oct; 86():92-99. PubMed ID: 27497159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secukinumab for rheumatology: development and its potential place in therapy.
    Koenders MI; van den Berg WB
    Drug Des Devel Ther; 2016; 10():2069-80. PubMed ID: 27445458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic Therapies for Autoimmune and Connective Tissue Diseases.
    Wolfe RM; Ang DC
    Immunol Allergy Clin North Am; 2017 May; 37(2):283-299. PubMed ID: 28366477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secukinumab: first global approval.
    Sanford M; McKeage K
    Drugs; 2015 Feb; 75(3):329-38. PubMed ID: 25648267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.
    Toussirot E
    Inflamm Allergy Drug Targets; 2012 Apr; 11(2):159-68. PubMed ID: 22280236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive γ/δ T cells in patients with active ankylosing spondylitis.
    Kenna TJ; Davidson SI; Duan R; Bradbury LA; McFarlane J; Smith M; Weedon H; Street S; Thomas R; Thomas GP; Brown MA
    Arthritis Rheum; 2012 May; 64(5):1420-9. PubMed ID: 22144400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased CCR4 expression on circulating CD4(+) T cells in ankylosing spondylitis, rheumatoid arthritis and systemic lupus erythematosus.
    Yang PT; Kasai H; Zhao LJ; Xiao WG; Tanabe F; Ito M
    Clin Exp Immunol; 2004 Nov; 138(2):342-7. PubMed ID: 15498047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-9 and T helper type 9 cells in rheumatic diseases.
    Ciccia F; Guggino G; Ferrante A; Cipriani P; Giacomelli R; Triolo G
    Clin Exp Immunol; 2016 Aug; 185(2):125-32. PubMed ID: 27159882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biological therapy of arthritis and systemic autoimmune diseases].
    Tamási L; Szekanecz Z
    Orv Hetil; 2007 Apr; 148 Suppl 1():63-70. PubMed ID: 17430797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-17 and innate immunity in infections and chronic inflammation.
    Isailovic N; Daigo K; Mantovani A; Selmi C
    J Autoimmun; 2015 Jun; 60():1-11. PubMed ID: 25998834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of interleukin-17 in inflammation and autoimmune diseases.
    Yan JW; Wang YJ; Peng WJ; Tao JH; Wan YN; Li BZ; Mei B; Chen B; Yao H; Yang GJ; Li XP; Ye DQ; Wang J
    Expert Opin Ther Targets; 2014 Jan; 18(1):29-41. PubMed ID: 24147601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases.
    Williams RO; Paleolog E; Feldmann M
    Curr Opin Pharmacol; 2007 Aug; 7(4):412-7. PubMed ID: 17627887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany.
    Huscher D; Merkesdal S; Thiele K; Zeidler H; Schneider M; Zink A;
    Ann Rheum Dis; 2006 Sep; 65(9):1175-83. PubMed ID: 16540552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis.
    Mease PJ
    Curr Opin Rheumatol; 2015 Mar; 27(2):127-33. PubMed ID: 25599143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases.
    Siebert S; Tsoukas A; Robertson J; McInnes I
    Pharmacol Rev; 2015; 67(2):280-309. PubMed ID: 25697599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis.
    Kirkham BW; Kavanaugh A; Reich K
    Immunology; 2014 Feb; 141(2):133-42. PubMed ID: 23819583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Th22 Cells Contribution in Immunopathogenesis of Rheumatic Diseases.
    Azizi G; Simhag A; El Rouby NM; Mirshafiey A
    Iran J Allergy Asthma Immunol; 2015 Jun; 14(3):246-54. PubMed ID: 26546892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides.
    Jandus C; Bioley G; Rivals JP; Dudler J; Speiser D; Romero P
    Arthritis Rheum; 2008 Aug; 58(8):2307-17. PubMed ID: 18668556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.